From Earlier: Cell Therapeutic Announces FDA's Oncologic Drugs Advisory Committee to Review Resubmitted Pixantrone New Drug Application on February 9, 2012

Cell Therapeutics, Inc. CTIC announced yesterday that on February 9, 2012 the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee will review CTI's resubmitted New Drug Application for pixantrone for the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma in patients who failed two or more lines of prior therapy. ODAC is a panel of experts that evaluates data concerning the efficacy and safety of marketed and investigational products for use in the treatment of cancer and makes recommendations to the FDA. The FDA will consider the recommendation of the panel, but the final decision regarding the approval of the product is made by the FDA.